WALTHAM, Mass.--(BUSINESS WIRE)--

Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced the appointment of Suzette Jaskie as Vice President Global Medical Affairs.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161013005181/en/

Suzette Jaskie joins Corindus Vascular Robotics as Vice President Global Medical Affairs (Photo: Business Wire)

Ms. Jaskie has 30 years of healthcare experience, the majority of which has been spent specifically in the cardiovascular field. Most recently, she served as President and Chief Executive Officer of MedAxiom Consulting. Prior to MedAxiom, she served as Executive Director of the Frederik Meijer Heart & Vascular Institute, Grand Rapids, MI, where she worked with co-medical directors to conceive, build and manage the multidisciplinary entity formed of 98 cardiovascular physician specialists and hospital administrators to manage the regional cardiovascular service line of Spectrum Health.

As Vice President Global Medical Affairs at Corindus, Ms. Jaskie will develop and execute best in class medical education programs focusing on robotic therapy and drive strategy for scientific, medical and industry conferences.

"I am very pleased to welcome Suzette to Corindus. As a veteran of the cardiovascular industry, she brings extensive knowledge and hands-on experience with distinguished medical organizations. I am looking forward to partnering with her as we continue to prove the benefits of robotic therapy to physicians, patients and hospitals," said Corindus CEO, Mark J. Toland.

"I am thrilled to join Corindus at this transformational point in the company’s growth. I look forward to working with Mark, CMO Dr. Grantham, and the entire Corindus team to build centers of excellence and further educate the interventional cardiology community on the benefits of robotic therapy," said Ms. Jaskie.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath^® System is the first FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005181/en/